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The development of gastric cancer is closely associated with
Helicobacter pylori (H. pylori ) infection. The expression of
cylooxigenase-2 (COX-2), a rate-limiting enzyme for prostaglandin
biosynthesis, is induced in H. pylori-associated chronic gastritis,
which thus results in the induction of proinflammatory prostaglandin,
PGE2. The COX-2/PGE2 pathway plays a key role in gastric
tumorigenesis. On the other hand, several oncogenic pathways
have been shown to trigger gastric tumorigenesis. The activation of
Wnt/b-catenin signaling is found in 30–50% of gastric cancers, thus
suggesting that Wnt signaling plays a causal role in gastric cancer
development. Mutations in the bone morphogenetic protein (BMP)
signaling pathway are responsible for the subset of juvenile
polyposis syndrome (JPS) that develops hamartomas in the
gastrointestinal tract. BMP suppression appears to contribute to
gastric cancer development because gastric cancer risk is increased
in JPS. Wnt signaling is important for the maintenance of
gastrointestinal stem cells, while BMP promotes epithelial cell
differentiation. Accordingly, it is possible that both Wnt activation
and BMP suppression can cause gastric tumorigenesis through
enhancement of the undifferentiated status of epithelial cells.
Recent mouse model studies have indicated that induction of the
PGE2 pathway is required for the development of both gastric
adenocarcinoma and hamartoma in the Wnt-activated and BMP-
suppressed gastric mucosa, respectively. This article reviews the
involvement of the PGE2, Wnt, and BMP pathways in the development
of gastric cancer, and gastric phenotypes that are found in transgenic
mouse models of PGE2 induction, Wnt activation, BMP suppression, or
a combination of these pathways. (Cancer Sci 2009; 100: 1779–1785)
Epidemiological studies indicate that the regular use ofnonsteroidal anti-inflammatory drugs (NSAIDs) lowers the
mortality rate of gastrointestinal cancer.(1) The major target of
NSAIDs is cyclooxygenases (COXs), COX-1 and COX-2, which
are rate-limiting enzymes for prostaglandin biosynthesis (Fig. 1).
COX-1 is constitutively expressed in most tissues and it is
considered to be responsible for physiological levels of
prostaglandin.(2) In contrast, COX-2 is induced in inflammation
by various stimuli including cytokines and growth factors.(3–5)
The induction of COX-2 expression is also found in a variety of
cancer tissues. Mouse genetic studies have demonstrated that
disruption of the Ptgs2 gene encoding COX-2 results in the
suppression of tumor development in the intestine and skin.(6,7)
Moreover, various animal studies have confirmed that treatment
with NSAIDs or COX-2 selective inhibitors (COXIBs) suppressed
chemically induced tumor formation and xenografted tumor
growth.(8) These results, taken together, indicate that the COX-2
pathway plays an essential role in cancer development.
However, the mechanism of the COX-2 pathway underlying
gastric tumorigenesis has not yet been fully elucidated. To
investigate the possible crosstalk between the COX-2 pathway
and oncogenic activation in gastric carcinogenesis, a series of
mouse models have been constructed and examined as discussed
in this review.
Induction of the COX-2/PGE2 pathway in gastric cancer
Regular use of NSAIDs is associated with a decreased incidence
of gastric cancer.(9–12) Induction of COX-2 is found in approximately
70% of gastric cancer, whereas the expression of COX-1 is not
elevated.(13,14) Gastric cancer can be divided into two histological
subtypes: intestinal and diffuse types, and the expression of
COX-2 is found predominantly in the intestinal-type gastric
cancer.(15) These results suggest that the COX-2 pathway plays a
role in the development of intestinal-type gastric cancer.
Infection with Helicobacter pylori (H. pylori) causes chronic
gastritis, which is associated with gastric carcinogenesis.(16) The
expression of COX-2 is significantly induced in the H. pylori-
infected gastric mucosa, and that COX-2 expression is suppressed
by the eradication of H. pylori.(17) Although the molecular mech-
anism for COX-2 induction in tumors has not been elucidated, it
is possible that the cytokine network is activated by infection
and induces the expression of COX-2. H. pylori can stimulate
Toll-like receptors (TLRs), leading to activation of the nuclear
factor-κB (NF-κB) pathway that induces the expression of COX-2
(Fig. 1).(18,19) Moreover, TLR2/TLR9 signaling by H. pylori
activates mitogen activated protein kinases (MAPK) including
p38, resulting in the activation of CRE and AP-1 elements on
the COX-2 gene promoter.(19,20)
Microsomal PGE synthase-1 (mPGES-1), a PGE2 converting
enzyme is functionally coupled with COX-2.(21) Simultaneous
induction of COX-2 and mPGES-1 is observed in gastric cancer
tissues suggesting induction of the PGE2 pathway in gastric tumors(Fig. 1).(22,23) The level of mPGES-1 also decreases after the
eradication of H. pylori,(24) thus indicating that H. pylori infection
induces the PGE2 pathway through induction of both COX-2 and
mPGES-1. The PGE2 level significantly increases in gastric cancer,(25)
and the level is associated with the H. pylori infection status.(26)
Gastric tumor development in mouse and rat models induced
by chemical carcinogens or Helicobacter infection is suppressed
by treatment with NSAIDs or COXIBs.(27–29) H. pylori infection
in Mongolian gerbils induces gastric tumorigenesis, which is
quite similar to the course of human gastric carcinogenesis.
Importantly, treatment with H. pylori-infected and chemical
carcinogen-treated Mongolian gerbils with a COXIB suppressed
gastric carcinogenesis.(30,31) These animal studies suggest that the
COX-2 pathway thus plays an essential role in H. pylori infection–
associated gastric tumorigenesis.
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K19-C2mE transgenic mice: A model for PGE2 induction in 
the stomach
K19-C2mE transgenic mice express both COX-2 and mPGES-1
in gastric epithelial cells, which results in induction of the PGE2
pathway in the stomach (Fig. 2).(32) K19-C2mE mice develop
hyperplastic lesions in the glandular stomach. Histologically, the
major cell type of hyperplasia is the mucous cell, which is similar
to that found in the spasmolytic polypeptide/TFF2-expressing
metaplasia (SPEM; Fig. 2).(33) The development of SPEM is
associated with an H. pylori infection and gastric adenocarcinoma,
thus suggesting that SPEM is an H. pylori-induced precancerous
lesion.(34) It is thus possible that the PGE2 pathway induced by
H. pylori infection is responsible for the development of SPEM.
Treatment with N-methyl-N-nitrosourea (MNU) to the H. pylori-
infected mice causes gastric tumor development. Notably, the
multiplicity of gastric tumors induced by H. pylori infection and
MNU treatment was significantly higher in K19-C2mE mice
compared with wild-type mice.(35) These results suggest that
PGE2-induced metaplastic hyperplasia is a precursor for chemical
carcinogen-induced gastric tumor.
Notably, macrophages infiltrate and are activated in the gastric
mucosa of K19-C2mE mice.(32) The activation of these macro-
phages is suppressed by treatment with antibiotics, thus indicating
that infectious stimuli activate the accumulated macrophages.
Importantly, the development of SPEM is also suppressed by
antibiotic treatment, thus suggesting that bacterial infection
activates macrophages, which is required for SPEM development.
Consistently, disruption of the tumor necrosis factor (TNF )-α
gene in K19-C2mE mice results in the suppression of SPEM
development, thus suggesting that TNF-α derived from activated
macrophages plays an essential role in SPEM formation.(33)
Moreover, it is conceivable that the induction of PGE2 signaling
is the primary cause for the mucosal macrophage accumulation,
because the treatment of K19-C2mE mice with a COXIB, but
not with antibiotics, inhibits macrophage infiltration. A possible
mechanism for the processes from H. pylori infection to SPEM
development through PGE2 induction and macrophage activation
is depicted in Figure 1.
Activation of Wnt signaling in gastric cancer
Canonical Wnt signaling (Wnt/β-catenin signaling) is a critical
pathway in the regulation of development as well as in
tumorigenesis.(36) In the absence of the Wnt ligand, cytoplasmic
β-catenin is phosphorylated by GSK-3β within a complex containing
adenomatous polyposis coli (APC) and Axin, thus resulting
in the degradation of β-catenin through the ubiquitin
proteasome pathway.(37) When Wnt ligands bind Frizzled receptors,
phosphorylation of β-catenin is suppressed, leading to stabilization
and nuclear translocation of β-catenin (Fig. 3). Nuclear β-catenin
interacts with T-cell factor/lymphocyte enhancer factor (TCF/
LEF) to induce transcription of Wnt target genes. APC or β-
catenin mutation causes tumor development by activation of the
canonical Wnt signaling.
Patients with germ-line mutations in the APC gene have an
increased risk of gastric cancer.(38) Moreover, β-catenin accumu-
lation, a hallmark of Wnt activation, is found in 30–50% of gastric
cancers.(39,40) These results suggest that Wnt activation is one of
the major causes of gastric cancer development. In gastric cancer,
mutations in β-catenin are reported, while APC mutations are
rarely detected.(41–43) However, the incidence of β-catenin mutations
is less than 30% in the Wnt-activated gastric cancers,(39) thus
suggesting mechanism(s) other than APC or β-catenin mutation
for activation of the Wnt pathway. It has been suggested that the
cytoplasmic β-catenin level is increased by E-cadherin downregu-
lation or β-TrCP mutation through decrease of E-cadherin-bound
membrane β-catenin or inhibition of β-catenin ubiquitination,
respectively (Fig. 3).(44,45) These mechanisms may thus contribute
to the activation of Wnt signaling in gastric tumorigenesis. On
the other hand, the expression of the SFRP1, -2, and -5 genes
are silenced by promoter methylation in gastric cancer cells.(46)
SFRPs are secreted endogenous antagonist of the Wnt ligands.
Accordingly, it is possible that SFRP methylation is also an
Fig. 1. Schematic presentation of arachidonic acid
metabolism in the context of gastric tumorigenesis.
The expression of cyclooxygenase (COX)-2 and
microsomal PGE synthase-1 (mPGES-1) is induced
by Helicobacter pylori (H. pylori)-associated
inflammatory responses. The simultaneous
expression of both COX-2 and mPGES-1 leads to
induction of the prostaglandin PGE2 pathway,
which results in macrophage accumulation. These
macrophages are activated by infectious stimuli,
resulting in the induction of tumor necrosis factor
(TNF)-α-dependent SPEM development and the
promotion of Wnt signaling, which may contribute
to gastric tumorigenesis. The induction of
angiogenesis and activation of epidermal growth
factor receptor (EGFR) signaling are also possible
mechanisms of PGE2 in tumorigenesis. COXIBs,
COX-2 selective inhibitors; NF-κB, nuclear factor-κB;
NSAIDS, nonsteroidal anti-inflammatory drugs;
SPEM, spasmolytic polypeptide/TFF2-expressing
metaplasia; TLRs, Toll-like receptors.
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important mechanism for Wnt activation in gastric tumorigenesis
(Fig. 3).(46)
K19-Wnt1 transgenic mice: A model for Wnt activation in 
the stomach
K19-Wnt1 transgenic mice express Wnt1, one of the canonical
Wnt ligands, in the gastric epithelial cells, which results in the
activation of Wnt signaling in the stomach (Fig. 2).(40) The number
of undifferentiated epithelial cells increases in the K19-Wnt1
mouse stomach, thus suggesting that Wnt signaling keeps gastric
epithelial cells in an undifferentiated status. Small preneoplastic
lesions spontaneously develop in the gastric mucosa of K19-Wnt1
mice, which consist of dysplastic epithelial cells (Fig. 2). However,
gastric tumors do not develop in K19-Wnt1 mice. It is thus possible
that the activation of Wnt signaling can trigger tumorigenesis
and form small preneoplastic lesions; however, Wnt activation
alone is not sufficient for tumor development (Fig. 3).
To examine the effect of the PGE2 pathway in the Wnt-activated
gastric mucosa, K19-Wnt1 mice were crossed with K19-C2mE
to construct compound transgenic mice (K19-Wnt1/C2mE mice),
in which both the Wnt and PGE2 pathways were activated in the
stomach simultaneously. Importantly, K19-Wnt1/C2mE mice
developed gastric adenocarcinoma (Fig. 2).(40) The tumors con-
sisted of dysplastic epithelial cells, which sometimes invade the
smooth muscle layers. These results clearly indicate that the
simultaneous activation of the Wnt and PGE2 pathways is
responsible for the development of gastric adenocarcinomas.
Importantly, the gene expression profile of K19-Wnt1/C2mE
mouse gastric tumors is similar to that of human intestinal-
type gastric cancer (Hiraku Itadani et al., submitted manuscript,
2009). Therefore, K19-Wnt1/C2mE mice recapitulate human
intestinal-type gastric cancer not only in the molecular etiology,
but also in the pathological and molecular characteristics of
tumors.
These results of mouse model studies suggest the following
possible scenario for gastric tumorigenesis (Fig. 3): H. pylori
infection causes the induction of the COX-2/PGE2 pathway,
which thus leads to SPEM development. The activation of Wnt
signaling in the normal gastric mucosa causes small preneoplastic
lesions, but is not sufficient for tumor formation. When Wnt sig-
naling is activated in the PGE2 induction–associated inflamed
mucosa, gastric adenocarcinomas develop through cooperation
of the Wnt and PGE2 pathways.
Suppression of BMP signaling in gastric tumors
Juvenile polyposis syndrome (JPS) is characterized by hereditary
gastrointestinal hamartomatous polyposis,(47) a subset of which
is caused by germline mutations in the BMP receptor type IA
gene (BMPR1A).(48) BMP ligands bind to a complex of the BMP
receptor type II and I, leading to phosphorylation of Smad1,5,8,
thereby allowing them to form a complex with Smad4.(49,50)
These Smad complexes translocate to the nuclei and function as
transcription enhancers. BMP signaling inhibits epithelial
proliferation and promotes differentiation.(51,52) The suppression
of BMP signaling in the mouse intestine results in hamartomatous
polyp development,(52,53) elongated villi, and crypt fission.(54) These
results suggest that the suppression of BMP signaling causes
tumorigenesis by the inhibition of epithelial cell differentiation.
Although the main affected site in JPS patients is the intestine,
gastric polyps also develop in JPS, and the cancer risk in JPS
patients increases both in the colon and stomach.(55,56) Moreover,
the expression of BMP-2 is suppressed by promoter methylation
Fig. 2. Transgenic mouse models of gastric
tumorigenesis. Transgenic vector construction(s)
and representative macroscopic and microscopic
photographs of the stomach are shown for each
line. K19-Wnt1/C2mE and K19-Nog/C2mE are
compound transgenic mice of K19-Wnt1 and K19-
C2mE, and K19-Nog and K19-C2mE, respectively.
The arrowhead in the K19-Wnt1 mouse stomach
indicates a preneoplastic lesion. The arrowheads
and asterisks in the K19-C2mE mouse stomach
indicate gastric hyperplasia and mucous metaplasia
(SPEM), respectively. The arrows in K19-Wnt1/
C2mE and K19-Nog/C2mE indicate gastric tumors.
Note that the histology of the K19-Wnt1/C2mE
mouse shows dysplastic adenocarcinoma, while
that of the K19-Nog/C2mE mouse shows hamartoma
with dilated cystic structure. Bars indicate 100 μm.
(Reproduced from Oshima et al. Cancer Res, 69:
2729–33, 2009.) BMP, bone morphogenetic protein;
COX-2, cyclooxygenase-2; SPEM, spasmolytic
polypeptide/TFF2-expressing metaplasia.
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in gastric cancer cells,(57) and stimulation of gastric cancer cells
with BMP-2 suppresses proliferation.(58) These results suggest
that the inhibition of BMP signaling contributes to gastric
tumorigenesis through the suppression of differentiation.
K19-Nog transgenic mice: A model for BMP suppression in 
the stomach
K19-Nog mice express noggin, an endogenous BMP antagonist,
in the gastric epithelial cells, thus resulting in the inhibition of
BMP signaling in the stomach (Fig. 2).(59) Noggin is a polypeptide
that inhibits BMP signaling by binding the BMP ligands.(50)
In the K19-Nog mice, the phosphorylation of Smad1,5,8 is
suppressed in the gastric gland by BMP inhibition. However,
K19-Nog mice do not develop gastric lesions, and the histology
of the gastric mucosa is normal (Fig. 2). To examine the effect
of cooperation of BMP suppression and PGE2 induction, K19-Nog
mice were crossed with K19-C2mE to construct compound
transgenic mice (K19-Nog/C2mE mice), in which BMP signaling
is suppressed and the PGE2 pathway is induced in the gastric
mucosa. Importantly, K19-Nog/C2mE mice develop large tumors
in the glandular stomach (Fig. 2). These results indicate that the
suppression of BMP signaling is insufficient for gastric
tumorigenesis; however, the induction of the PGE2 pathway does
promote tumor formation in the BMP-suppressed gastric mucosa.
Histologically, K19-Nog/C2mE mouse tumors are not dysplastic,
but consist of irregular branching of epithelial cell layers, combined
with dilated cysts (Fig. 2). Such histological characteristics are
distinct from adenocarcinomas of K19-Wnt1/C2mE mice, but
are typical of the hamartomas of JPS patients.(55,56,60) These results
indicate that the suppression of BMP signaling associated with
PGE2 induction causes gastric hamartoma development. Accord-
ingly, it is possible that types of genetic alterations determine
the histological types of tumors, e.g. adenocarcinoma by Wnt
activation or hamartoma by BMP suppression. Furthermore, the
induction of the PGE2 pathway promotes tumor formation
regardless of the histological types (Fig. 2). Accordingly, it is
thus possible that H. pylori infection contributes to development
of both types of gastric tumors through PGE2 induction.
It has been reported that BMP signaling negatively regulates
Wnt signaling in the intestinal crypt.(53) Namely, suppression of
BMP signaling enhances Wnt activity through the activation of
PI3K/Akt pathway. However, the β-catenin level in the K19-
Nog/C2mE hamartomas is the same as that in the wild-type
Fig. 3. Schematic presentation of the canonical Wnt signaling and cyclooxygenase (COX)-2/prostaglandin PGE2 pathway in gastric tumor
development. β-Catenin mutations, SFRPs methylation, and downregulation of E-cadherin or β-TrCP can activate Wnt signaling in gastric cancer.
Cooperation of the Helicobacter pylori (H. pylori )-induced COX-2/PGE2 pathway with Wnt activation leads to the development of gastric
adenocarcinoma. Without the induction of the PGE2 pathway, Wnt activation alone does not cause gastric cancer development. mPGES-1,
microsomal PGE synthase-1.
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mouse stomach, while it is markedly elevated in K19-Wnt1/C2mE
gastric tumors.(59) These results indicate that gastric hamartomas
develop in K19-Nog/C2mE mice due to a Wnt-activation in-
dependent mechanism.
Possible mechanisms of the PGE2 pathway in gastric 
tumorigenesis
There are four G protein-coupled receptors for PGE2, EP1–EP4.
Among these receptors, the expression of EP4 increased
significantly in gastric tumors of both K19-Wnt1/C2mE mice
and K19-Nog/C2mE mice.(59) It is thus possible that PGE2 signaling
through EP4 plays a role in the development of adenocarcinoma
and hamartoma in the Wnt-activated and BMP-suppressed
gastric mucosa, respectively.
The promotion of the Wnt signaling activity beyond the basal
activation level may be important for malignant progression.(61)
For example, increased accumulation of β-catenin is found in
the invasion front of colon cancer, suggesting that the increased
Wnt activation level contributes to tumor invasion.(62) Hepatocyte
growth factor (HGF) and platelet-derived growth factor (PDGF)
increase the Wnt signaling activity in colon cancer cells,
suggesting that these factors function as Wnt promoters.(63,64)
Notably, the level of Wnt signaling activity in gastric cancer
cells significantly increases when the cells are stimulated with a
conditioned medium from activated macrophages (Fig. 4a).(65)
Moreover, TNF-α, but not other proinflammatory cytokines,
caused an increase in the Wnt signaling activity in gastric cancer
cells (Fig. 4b).(65) These results suggest the hypothesis that Wnt
activation, due to either genetic or epigenetic alterations in
normal epithelial cells, is not sufficient for gastric tumor develop-
ment. However, the Wnt activation level increases further in
the inflamed mucosa by macrophage-derived TNF-α, and such
Wnt promotion contributes to gastric cancer development (Fig. 4c).
The induction of the PGE2 pathway leads to macrophage
accumulation in the gastric mucosa. It is therefore conceivable that
the induction of Wnt promotion is one of the important mechanisms
of the PGE2 pathway in gastric tumorigenesis (Fig. 1).
Fig. 4. Promotion of Wnt signaling by macrophage-derived tumor necrosis factor (TNF)-α in gastric cancer cells. (a) Representative FACS analyses
of Wnt-reporter gastric cancer cells, AGS-GFP, in which GFP expression is regulated by β-catenin/TCF. GFP intensity increased significantly when cells
were treated with conditioned medium (CM) from activated macrophages. (b) GFP intensity of reporter cells treated with indicated cytokines are
shown in the bar graph. Note that Wnt activity is elevated by treatment with TNF-α in a dose-dependent manner. (c) Hypothesis for gastric tumor
development. The level of Wnt signaling activated by genetic /epigenetic alteration is not sufficient for tumorigenesis. However, Helicobacter pylori
(H. pylori ) infection-induced inflammation promotes the Wnt activation level through macrophage-derived TNF-α, which contributes to gastric
tumorigenesis. (a and b, reproduced from Oguma et al. EMBO J, 27: 1671–81, 2008, with permission from the Nature Publishing Group.)
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Conclusions
Studies with mouse models have elucidated the roles of the
PGE2 pathway in gastric tumorigenesis in the Wnt-activated and
BMP-suppressed gastric mucosa. Alterations in morphogen
signals, such as the Wnt and BMP pathways, can therefore
trigger gastric tumorigenesis by the suppression of epithelial
differentiation. However, alterations of these signals in the non-
inflamed stomach do not cause gastric tumor formation. In
contrast, alterations of these signals in the inflamed gastric
mucosa lead to the development of gastric tumors through
cooperation with the PGE2 pathway. Moreover, mouse studies
show the possible mechanisms of PGE2 in gastric tumorigenesis,
i.e. macrophage accumulation and activation, subsequent SPEM
formation, and Wnt signaling promotion. Considering the
multifunctional nature of PGE2, it is possible that other mechanisms
triggered by the PGE2 pathway may also contribute to gastric
tumorigenesis, which should be further elucidated using mouse
models in the future. These studies will provide a rationale for
the inhibition of the PGE2 pathway as a possible preventative
strategy against gastric tumorigenesis.
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